跳转至内容
Merck
CN

20051

Supelco

ORBO Amberlite XAD-2 管

W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea

别名:

ORBO 609 Amberlite XAD®-2 (20/50) 400/200 mg

登录查看公司和协议定价


About This Item

UNSPSC代码:
47131900

物料

W,W,W separators

质量水平

Agency

NIOSH 2534,2537

产品线

Amberlite
ORBO

组成

Bed A, 400 mg
Bed B, 200 mg

包装

pkg of 50 ea

制造商/商品名称

ORBO 609

技术

active air sampling: suitable

外径 × 长度

8 mm × 110 mm

基质

XAD-2

粒径

20-50 mesh

应用

air monitoring
environmental
industrial hygiene

正在寻找类似产品? 访问 产品对比指南

一般描述

ORBO 609 Amberlite XAD®-2 (20/50),400/200 mg吸附剂管(W,W,W 分离器,O.D. × L 8 mm × 110 mm)含有两个由玻璃丝或泡沫分开的相同的选择性吸附剂床层,用于气体和蒸汽采样。管的双层或双床层结构使得较小的后备床层可以捕集穿漏的样品。

法律信息

Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门